...
首页> 外文期刊>Toxicology and Applied Pharmacology >PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury
【24h】

PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury

机译:PPARγ激动剂,吡格列酮,肾缺血/再灌注损伤诱导的肝损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Remote organ damage is the major cause of death in patients with acute kidney injury (AKI) due to renal ischemia reperfusion (IR). Liver is one of the vital organs which are profoundly affected by AKI. The present study aims to investigate the role of peroxisome proliferator activator receptor gamma (PPAR gamma) in liver damage induced by IR injury in rats. Renal IR was induced by right nephrectomy, occlusion of left renal pedicle for 45 min to induce ischemia, and then reperfusion for 6 or 24 h. The PPAR gamma agonist, pioglitazone, was given orally for 7 days before renal IR procedure. Animals receiving pioglitazone showed improvement in renal and hepatic functions when compared to IR groups. Renal IR increased renal, hepatic and serum levels of tumor necrosis factor-alpha (TNF-alpha) and induced apoptotic cell death in liver. These effects were diminished with pioglitazone. In addition, pioglitazone reduced renal IR-induced oxidative stress in liver. Pioglitazone reduced malondialdehyde (MDA) content and NADPH oxidase mRNA expression and induced further increase in nuclear factor erythroid 2-related factor 2 (Nrf2) expression when compared to IR groups. Furthermore, pioglitazone increased the expression of PPAR gamma target genes such as renal and hepatic PPAR gamma 1 (Pparg1), hepatic hemoxygenase-1 (Hmox1), and hepatic thioredoxin (TRx). Histological profiles for kidney and liver were also ameliorated with pioglitazone. Hence, PPAR gamma is a potential target to protect liver in patients with renal IR injury.
机译:偏远器官损伤是由于肾缺血再灌注(IR),急性肾损伤(AKI)患者死亡的主要原因。肝脏是受AKI深受影响的重要机构之一。本研究旨在探讨过氧化物体增殖剂活化剂受体γ(PPARγ)在大鼠红外损伤诱导的肝损伤中的作用。肾红外用右肾切除诱导,左肾椎弓集闭塞45分钟以诱导缺血,然后再灌注6或24小时。 PPARγ激动剂Pioglitazone在肾红外手术前口服给予7天。与IR组相比,接受吡格列唑酮的动物显示出肾和肝功能的改善。肾红外肾脏,肝癌和血清水平增加肿瘤坏死因子-α(TNF-α)和肝脏诱导凋亡细胞死亡。吡格列酮减少了这些效果。此外,吡格列酮在肝脏中降低肾红外氧化胁迫。吡格列酮还原丙二醛(MDA)含量和NADPH氧化酶mRNA表达,并与IR组相比,核因子红细胞2相关因子2(NRF2)表达的进一步增加。此外,Pioglitazone增加了PPARγ靶基因,例如肾和肝PPARγ1(PPARG1),肝血氧酶-1(HMOX1)和肝硫醚(TRX)的表达。肾脏和肝脏的组织学曲线也与吡格列酮改善。因此,PPARγ是保护肝脏患者患者损伤的潜在目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号